

SUMMARY OF FINANCIAL STATEMENTS (CONSOLIDATED)

Financial Results for the Fiscal Year Ended March 31, 2010

May 12, 2010

These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan.

Takeda Pharmaceutical Company Limited

Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo

TSE Code: 4502

URL: <http://www.takeda.co.jp>

Representative: Yasuchika Hasegawa, President & CEO

Contact: Hiroshi Ohtsuki, Corporate Officer, Senior Vice President, Corporate Communications Department

Telephone: +81-3-3278-2037

Scheduled date of annual general meeting of shareholders: June 25, 2010

Scheduled date of securities report submission: June 25, 2010

Scheduled date of dividend payment commencement: June 28, 2010

(Millions of yen, rounded to the nearest million)

1. Consolidated Results for Fiscal 2009 (April 1, 2009-March 31, 2010)

(1) Consolidated Operating Results

(Percentage figures represent changes from same period of previous year)

	Net sales (¥ million)	Year-on-year change (%)	Operating income (¥ million)	Year-on-year change (%)	Ordinary income (¥ million)	Year-on-year change (%)
Fiscal 2009	1,465,965	(4.7)	420,212	37.1	415,829	27.1
Fiscal 2008	1,538,336	11.9	306,468	(27.6)	327,199	(39.0)

	Net income (¥ million)	Year-on-year change (%)	Earnings per share (¥)	Fully diluted earnings per share (¥)	Return on equity (%)	Ordinary income / total assets (%)	Operating margin (%)
Fiscal 2009	297,744	27.0	377.19	377.14	14.4	14.9	28.7
Fiscal 2008	234,385	(34.1)	289.82	289.80	10.9	11.7	19.9

(Reference) Equity in earnings of affiliate: Fiscal 2009 ¥837million
Fiscal 2008 ¥2,898million

(2) Consolidated Financial Position

	Total assets (¥ million)	Net assets (¥ million)	Shareholders' equity ratio (%)	Shareholders' equity per share (¥)
Fiscal 2009	2,823,274	2,164,745	75.1	2,687.14
Fiscal 2008	2,760,188	2,053,840	72.9	2,548.09

(Reference) Shareholders' equity Fiscal 2009 ¥2,121,173million
Fiscal 2008 ¥2,011,366million

(3) Consolidated Cash Flows

	Net cash provided by operating activities (¥ million)	Net cash provided by (used in) investing activities (¥ million)	Net cash provided by (used in) financing activities (¥ million)	Cash and cash equivalents at end of period (¥ million)
Fiscal 2009	381,168	(117,521)	(148,046)	852,480
Fiscal 2008	326,273	(767,256)	(425,840)	758,082

2. Dividends

Record date	Dividend per share (¥)					Total dividends (Annual) (¥ million)	Dividend Pay-out ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	End of 1 st quarter	End of first half	End of 3 rd quarter	Year-end	Annual			
Fiscal 2008	—	88.00	—	92.00	180.00	144,344	62.1	6.9
Fiscal 2009	—	90.00	—	90.00	180.00	142,103	47.7	6.9
Fiscal 2010 (Projection)	—	90.00	—	90.00	180.00	—	64.6	—

3. Projected Consolidated Results for Fiscal 2010 (April 1, 2010-March 31, 2011)

(Percentage figures represent changes from same period of previous year.)

	Net sales (¥ million)	Year-on- year change(%)	Operating income (¥ million)	Year-on- year change(%)	Ordinary income (¥ million)	Year-on- year change(%)	Net income (¥ million)	Year-on- year change(%)	Earnings per share (¥)
First half year	690,000	(8.7)	180,000	(25.8)	185,000	(27.4)	120,000	(36.7)	152.02
Fiscal 2010	1,400,000	(4.5)	330,000	(21.5)	340,000	(18.2)	220,000	(26.1)	278.70

4. Other

- (1) Significant changes in subsidiaries during period (changes in specified subsidiaries resulting in the change in consolidation scope): Yes
Elimination 1 company [Takeda Pharma Ireland Limited]
(Note) Refer to *The Takeda Group*, on page 17, for details.
- (2) Changes in accounting principles, procedures, method of presentation associated with preparation of the consolidated financial statements (matters to be included in the section, *Changes in Basic Important Matters for Preparation of Consolidated Financial Statements*)
1) Changes due to revisions of accounting standards etc.: No
2) Changes other than 1): No
- (3) Number of shares outstanding (common stock)
1) Number of shares outstanding at term end (including treasury stock):
March 31, 2010 789,666,095 shares
March 31, 2009 789,666,095 shares
2) Number of shares of treasury stock at term end
March 31, 2010 286,209 shares
March 31, 2009 302,797 shares
(Note) Refer to *Per Share Information*, on page 38, for number of shares that forms basis for calculating earnings per share.

(Reference) Summary of Unconsolidated Results

Summary of Unconsolidated Results for Fiscal 2009 (April 1, 2009 – March 31, 2010)

(1) Unconsolidated Operating Results

(Percentage figures represent changes from same period of previous year)

	Net sales (¥ million)	Year-on-year change (%)	Operating income (¥ million)	Year-on-year change (%)	Ordinary income (¥ million)	Year-on-year change (%)
Fiscal 2009	871,720	(0.3)	247,391	1.5	257,183	(4.6)
Fiscal 2008	874,079	(2.1)	243,727	(9.0)	269,653	(1.1)

	Net income (¥ million)	Year-on-year change (%)	Earnings per share (¥)	Fully diluted earnings per share (¥)
Fiscal 2009	206,362	38.0	261.40	261.37
Fiscal 2008	149,513	(14.4)	184.85	184.84

(2) Unconsolidated Financial Position

	Total assets (¥ million)	Net assets (¥ million)	Shareholders' equity ratio (%)	Shareholders' equity per share (¥)
Fiscal 2009	1,539,606	1,281,125	83.2	1,622.57
Fiscal 2008	1,470,631	1,211,731	82.4	1,534.80

(Reference) Shareholders' equity
Fiscal 2009 ¥ 1,280,959million
Fiscal 2008 ¥ 1,211,645million

* Note to ensure appropriate use of forecasts

Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc. (TPNA) brought patent infringement lawsuits against companies that had submitted Abbreviated New Drug Application (ANDA) for generic Actos (generic name: pioglitazone) and/or ACTOplus met (a fixed dose combination tablet of pioglitazone with metformin). Although until the lawsuits that are currently pending and those that would be brought against companies who may submit ANDA, if any, are resolved or concluded, the date of entry of generic Actos is uncertain, while preparing the fiscal 2010 financial outlook, Takeda is operating on the assumption that the entry of generic versions of Actos will be August, 2012.

The outlook presented in this presentation is the result of management's assessment based upon currently available information, and the actual performance could be influenced by various risks and uncertainties.

For further details, please refer to "1. Results of Operations (1) Analysis of Operation Results 5) Outlook for Fiscal 2010" on page 12.